Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
Pharmaceutics · 30.11.2023 · 15 (12) · 2712
DOI: 10.3390/pharmaceutics15122712 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 30.11.2023. Verfasst von Luigia Meo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biology, University of Salerno, Via Giovanni Paolo II, 132, 84084 Salerno, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Most commonly diagnosed cancer pathologies in the pediatric population comprise leukemias and cancers of the nervous system. The percentage of cancer survivors increased from approximatively 50% to 80% thanks to improvements in medical treatments and the introduction of new chemotherapies. However, as a consequence, heart disease has become the main cause of death in the children due to the cardiotoxicity induced by chemotherapy treatments. The use of different cardiovascular biomarkers, complementing data obtained from electrocardiogram, echocardiography cardiac imaging, and evaluation of clinical symptoms, is considered a routine in clinical diagnosis, prognosis, risk stratification, and differential diagnosis. Cardiac troponin and natriuretic peptides are the best-validated biomarkers broadly accepted in clinical practice for the diagnosis of acute coronary syndrome and heart failure, although many other biomarkers are used and several potential markers are currently under study and possibly will play a more prominent role in the future. Several studies have shown how the measurement of cardiac troponin (cTn) can be used for the early detection of heart damage in oncological patients treated with potentially cardiotoxic chemotherapeutic drugs. The advent of high sensitive methods (hs-cTnI or hs-cTnT) further improved the effectiveness of risk stratification and monitoring during treatment cycles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry and Biology, University of Salerno, Via Giovanni Paolo II, 132, 84084 Salerno, Italy.
- Clinical Pathology, Santobono-Pausilipon Children's Hospital, 80123 Naples, Italy.
- Clinical and Translational Research Unit, Santobono-Pausilipon Children's Hospital, 80123 Naples, Italy.
ORCID-Profile: Luigia Meo, Peppino Mirabelli, Mariaevelina Alfieri
Zitieren
APA
Meo, L., Savarese, M., Munno, C., Mirabelli, P., Ragno, P., Leone, O., & Alfieri, M. (2023). Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children. Pharmaceutics, 15(12), 2712. https://doi.org/10.3390/pharmaceutics15122712
Vancouver
Meo L, Savarese M, Munno C, Mirabelli P, Ragno P, Leone O, et al. Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children. Pharmaceutics. 2023;15(12):2712. doi:10.3390/pharmaceutics15122712
BibTeX
@article{Meo2023,
author = {Meo, Luigia and Savarese, Maria and Munno, Carmen and Mirabelli, Peppino and Ragno, Pia and Leone, Ornella and Alfieri, Mariaevelina},
title = {Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {12},
pages = {2712},
doi = {10.3390/pharmaceutics15122712}
}
EUVIMED